Cargando…
B-cell lymphoma 2 family members and sarcomas: a promising target in a heterogeneous disease
Targeting the B-cell lymphoma 2 (Bcl-2) family proteins has been the backbone for hematological malignancies with overall survival improvements. The Bcl-2 family is a major player in apoptosis regulation and, has captured the researcher’s interest in the treatment of solid tumors. Sarcomas are a het...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Open Exploration Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501895/ https://www.ncbi.nlm.nih.gov/pubmed/37720343 http://dx.doi.org/10.37349/etat.2023.00154 |
_version_ | 1785106204720103424 |
---|---|
author | Oliveira, Rui Caetano Gama, João Casanova, José |
author_facet | Oliveira, Rui Caetano Gama, João Casanova, José |
author_sort | Oliveira, Rui Caetano |
collection | PubMed |
description | Targeting the B-cell lymphoma 2 (Bcl-2) family proteins has been the backbone for hematological malignancies with overall survival improvements. The Bcl-2 family is a major player in apoptosis regulation and, has captured the researcher’s interest in the treatment of solid tumors. Sarcomas are a heterogeneous group of diseases, comprising several entities, with high morbidity and mortality and with few specific therapies available. The treatment for sarcomas is based on platinum regimens, with variable results and poor outcomes, especially in advanced lesions. The high number of different sarcoma entities makes treatment standardization as well as the performance of clinical trials difficult. The use of Bcl-2 family members modifiers has revealed promising results in in vitro and in vivo models and may be a valid option, especially when used in combination with chemotherapy. In this article, a revision of these results and possibilities for the use of Bcl-2 family members inhibitors in sarcomas was performed. |
format | Online Article Text |
id | pubmed-10501895 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Open Exploration Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-105018952023-09-16 B-cell lymphoma 2 family members and sarcomas: a promising target in a heterogeneous disease Oliveira, Rui Caetano Gama, João Casanova, José Explor Target Antitumor Ther Review Targeting the B-cell lymphoma 2 (Bcl-2) family proteins has been the backbone for hematological malignancies with overall survival improvements. The Bcl-2 family is a major player in apoptosis regulation and, has captured the researcher’s interest in the treatment of solid tumors. Sarcomas are a heterogeneous group of diseases, comprising several entities, with high morbidity and mortality and with few specific therapies available. The treatment for sarcomas is based on platinum regimens, with variable results and poor outcomes, especially in advanced lesions. The high number of different sarcoma entities makes treatment standardization as well as the performance of clinical trials difficult. The use of Bcl-2 family members modifiers has revealed promising results in in vitro and in vivo models and may be a valid option, especially when used in combination with chemotherapy. In this article, a revision of these results and possibilities for the use of Bcl-2 family members inhibitors in sarcomas was performed. Open Exploration Publishing 2023 2023-08-24 /pmc/articles/PMC10501895/ /pubmed/37720343 http://dx.doi.org/10.37349/etat.2023.00154 Text en © The Author(s) 2023. https://creativecommons.org/licenses/by/4.0/This is an Open Access article licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Review Oliveira, Rui Caetano Gama, João Casanova, José B-cell lymphoma 2 family members and sarcomas: a promising target in a heterogeneous disease |
title | B-cell lymphoma 2 family members and sarcomas: a promising target in a heterogeneous disease |
title_full | B-cell lymphoma 2 family members and sarcomas: a promising target in a heterogeneous disease |
title_fullStr | B-cell lymphoma 2 family members and sarcomas: a promising target in a heterogeneous disease |
title_full_unstemmed | B-cell lymphoma 2 family members and sarcomas: a promising target in a heterogeneous disease |
title_short | B-cell lymphoma 2 family members and sarcomas: a promising target in a heterogeneous disease |
title_sort | b-cell lymphoma 2 family members and sarcomas: a promising target in a heterogeneous disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501895/ https://www.ncbi.nlm.nih.gov/pubmed/37720343 http://dx.doi.org/10.37349/etat.2023.00154 |
work_keys_str_mv | AT oliveiraruicaetano bcelllymphoma2familymembersandsarcomasapromisingtargetinaheterogeneousdisease AT gamajoao bcelllymphoma2familymembersandsarcomasapromisingtargetinaheterogeneousdisease AT casanovajose bcelllymphoma2familymembersandsarcomasapromisingtargetinaheterogeneousdisease |